NR1H4 and metabolic dysfunction-associated steatohepatitis: This vigilance is particularly relevant given that other candidate therapies for MASH, such as the Farnesoid X receptor (FXR) agonist obeticholic acid, have failed to gain FDA approval, largely due to the risk of DILI [30].